Program summary
Detailed program
8th June 2017
Sponsored Symposium – Kowa
14:30 - 16:30
“Update in the management of dyslipidemia for vascular prevention in patients with type 2 diabetes”
Co-chairs:
• Prof. Evgeny Shlyakhto
President of the Russian Society of Cardiology
• Professor Yuji Matsuzawa
President of the International Atherosclerosis Society
  • Macrovascular complications of type 2 diabetes: Evidence of the role of atherogenic dyslipidemia
    Prof. Jesus Millan
    Hospital Gl Univ. Gregorio Maranon, Madrid, Spain
  • Microvascular complications of type 2 diabetes: Opportunity of pharmacological treatment
    Prof. Michel Hermans
    Cliniques Universitaires Saint-Luc Brussels, Belgium (General Secretary of R3i)
  • Management of cholesterol in patients with type 2 diabetes: Benefit and risk of statins
    Prof. Peter Toth
    CGH Medical Center, Sterling, IL and the University of Illinois School of Medicine, Peoria, IL
  • Management of atherogenic dyslipidemia as residual vascular risk: Efficacy and safety of a novel selective peroxisome proliferator-activated receptorα modulator (SPPARMα)
    Prof. Shun Ishibashi
    Jichi Medical University, Japan
  • Total management of dyslipidemia: Effects of SPPARMα on HDL function and postprandial hyperlipidemia
    Prof. Shizuya Yamashita
    Osaka University Graduate School of Medicine / Rinku General Medical Center, Japan
The Opening Ceremony
17:00 - 18:00
Opening Speeches from:
Jean-Charles Fruchart (President of R3i Foundation)
Eugeny Schlyakhto (President of Russian Society of Cardiology)
Yuji Matsuzawa (President of International Atherosclerosis Society)
Lale Tokgözoglu (Elect of European Atherosclerosis Society)
Shaukat Sadikot (President of International Diabtes Federation)
Awarding R3i Foundation Prize to Professor Jean Davignon
Plenary Session
Chair: Jean Davignon
  • Jean-Charles Fruchart
    “Residual Risk in diabetic patients: lessons from recent genetic studies”
  • Eugeny Schlyakhto
    “Changing Paradigm of Metabolic Syndrome”
9th June 2017
Metabolic Syndrome – Where are we now?
8:30 - 10:30
Chairs: Y. Matsuzawa, E.Baranova
  • Genetics and Metabolic Syndrome: Expectations and Disappointments
    A. Kostareva (Russia)
  • Non alcoholic fatty liver disease and atherosclerosis
    Raul Santos (Brazil)
  • Sleep Apnea and Comorbidities
    A. Conrady (Russia)
  • The Tides Turn on Triglycerides
    Peter Libby (USA)
Emerging therapies in the treatment of Atherosclerosis
11:30 - 13:00
Chairs: P. Ridker, R. Santos
  • Residual Inflammatory Risk and Residual Triglyceride Risk: What Trials May Tell Us
    P. Ridker (USA)
  • GLAGOV Study: Effect of intensive LDL lowering In Patients With Coronary Artery Disease
    Wolfgang Koenig (Germany)
  • Novel therapeutic targets for cardiovascular calcification
    Elena Aikawa (USA)
  • Familial Hyperlipidemia
    M. Ezhov (Russia)
Management of Cardiovascular Risk in Patients with Diabetes Mellitus
14:00 - 16:00
Chairs: S. Yamashita and P. Libby
  • Diabetes Mellitus Type 2 Treatment – Cardiovascular Mortality Reduction
    E. Grineva (Russia)
  • Treatment of diabetes and its effect on body weight
    S. Sadikot (India)
  • Selective PPARa modulator (SPPARMa), a new drug for the reduction of macro and microvascular od diabetes type II
    JC Fruchart (France)
  • New Mechanisms for Macrophage Activation in Cardiometabolic Disease
    Masanori Aikawa (USA)
Metabolic Syndrome and Biomarkers: what have we learned?
16:30 - 18:30
Chairs: M. Hermans, S. Sadikot
  • Subclinical atherosclerosis imaging in Metabolic Syndrome: Is it worth doing ?
    Lale Tokgözoglu (Turkey)
  • Triglyceride rich lipoproteins and atherosclerotic cardiovascular disease
    Berge G. Nordestgaarid (Danmark)
  • Metabolic Syndrome and Epicardial Fat
    E. Baranova (Russia)
  • How can we influence biomarkers in everyday clinical practice?
    Richard Ceska (Czech Republic)
10th June 2017
Arterial Hypertension and Comorbidities
9:00 - 11:00
Chairs: A. Conrady, D. Duplyakov
  • Hypertension and Obesity - Old Problem. What is New?
    Zh. Kobalava (Russia)
  • Combined Therapy in Dyslipidemic Patients
    S. Gilyarevsky (Russia)
  • Hypertension, Hyperuricemia and Kidney Damage
    S. Villevalde (Russia)
  • Hypertension in Very Elderly Frail Patients
    Yu. Kotovskaya (Russia)
Obesity and Comorbidities
11:00 - 13:00
Chairs: Zh. Kobalava, S.Nedogoda
  • Obesity, Metabolic Syndrome and Cognitive Disorders
    S. Janishevsky (Russia)
  • Compliance and Pharmacological Therapy
    A. Nedoshivin (Russia)
  • Management of Obesity: New Aspects
    A. Volkova (Russia)
  • Bariatric Surgery and Diabetes Mellitus Type 2, Cardiovascular Events
    A. Neimark (Russia)
Organized by:
R3i russian_society_of_cardiology
 
Under the AEGIS of:
European Atherosclerosis Society International Atherosclerosis Society